Case-Based Roundtable Meetings Spotlight: April 1 2022

April 21, 2022

Scott S. Tykodi, MD, PhD, and Ulka N. Vaishampayan, MBBS, discussed treatment for patients with relapsed and late-stage renal cell carcinoma based on National Comprehensive Cancer Network guidelines and recent clinical trials.

April 20, 2022

During a Targeted Oncology case-based roundtable event, Matthew A. Davids, MD, MMSc, discussed key considerations for prophylaxis and the use of rasburicase in managing tumor lysis syndrome.

April 20, 2022

During a Targeted Oncology case-based roundtable event, Srdan Verstovsek, MD, PhD, discussed the procedure of prognosis, biopsy, and treatment of a 68-year-old woman with myelofibrosis.

April 19, 2022

During a Targeted Oncology case-based roundtable event, John M. Burke, MD, discussed decision-making for third-line therapy for an elderly patient with diffuse large B-cell lymphoma.

April 18, 2022

During a Targeted Oncology case-based roundtable discussion, Krishnansu S. Tewari, MD, discussed the use of bevacizumab, niraparib, and olaparib for patients who have completed primary chemotherapy for advanced ovarian cancer.

April 16, 2022

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed the CARD trial of cabazitaxel and the VISION trial of lutetium-177 for patients with metastatic castration-resistant prostate cancer.

April 15, 2022

During a Targeted Oncology case-based roundtable event, Thomas Hutson, DO, PharmaD, discussed immunotherapy and tyrosine kinase inhibitor combinations for frontline therapy of renal cell carcinoma.